Shareholder Weng Zhanguo of Shanxi C&Y Pharmaceutical Group (stock code: 300254.SZ) plans to reduce his shareholding by no more than 3%.
Qiandian Pharmaceutical (300254.SZ) announced that the company's shareholder, Weng Zhanguo, plans to reduce his shares from November 13, 2025 to 2...
Shanxi C&Y Pharmaceutical Group (300254.SZ) announced that the company's shareholder, Weng Zhanguo, plans to reduce his holdings of the company's shares through centralized bidding and block trading from November 13, 2025 to February 12, 2026, with a maximum of 7.6831 million shares (not exceeding 3% of the total share capital of the company).
Related Articles
BJ ENT WATER (00371) has appointed Li Li as the chief expert.
Industrial and Commercial Bank of China (01398) completes the issuance of 2025 non-capital loss-absorbing bond (first tranche) (bond connect)
SUPERACTIVE GP(00176) has received a court summons and will continue to be suspended from trading.
BJ ENT WATER (00371) has appointed Li Li as the chief expert.
Industrial and Commercial Bank of China (01398) completes the issuance of 2025 non-capital loss-absorbing bond (first tranche) (bond connect)
SUPERACTIVE GP(00176) has received a court summons and will continue to be suspended from trading.
RECOMMEND
Why European Automakers Are Opposing Dutch Sanctions
20/10/2025
Domestic Commercial Rockets Enter Batch Launch Era: Behind the Scenes a Sixfold Cost Gap and Reusability as the Key Breakthrough
20/10/2025
Multiple Positive Catalysts Lift Tech Stocks; UBS Elevates China Tech to Most Attractive, Citing AI as Core Rationale
20/10/2025
